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Abstract
Radioiodinated recombinant human interferon-gamma (IFN-y)
bound to human monocytes, U937, and HL60 cells in a specific,
saturable, and reversible manner. At 40C, the different cell types
bound 3,000-7,000 molecules of IFNy, and binding was of com-
parable affinity (K. = 4-12 X 10 M-l). No change in the receptor
was observed after monocytes differentiated to macrophages or
when the cell lines were pharmacologically induced to differ-
entiate. The functional relevance of the receptor was validated
by the demonstration that receptor occupancy correlated with
induction of Fc receptors on U937. Binding studies using U937
permeabilized with digitonin showed that only 46% of the total
receptor pool was expressed at the cell surface. The receptor
appears to be a protein, since treatment of U937 with trypsin or
pronase reduced '251-IFNy binding by 87 and 95%, respectively.
At 370C, ligand was internalized, since 32% of the cell-associated
IFNy became resistant to trypsin stripping. Monocytes degraded
'251-IFNy into trichloroacetic acid-soluble counts at 370C but
not at 40C, at an approximate rate of 5,000 molecules/cell per
h. The receptor was partially characterized by SDS-polyacryl-
amide gel electrophoresis analysis of purified U937 membranes
that had been incubated with _251-IFNy. After cross-linking, the
receptor-ligand complex migrated as a broad band that displayed
an M, of 104,000±18,000 at the top and 84,000±6,000 at the
bottom. These results thereby define and partially characterize
the IFNy receptor of human mononuclear phagocytes.
Introduction
Macrophage activation has been defined as a series of functional
and biochemical modifications in macrophage populations (1-
4) that are induced by a T cell-derived lymphokine known as
macrophage activating factor (MAF).' Previous reports from
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1. Abbreviations used in this paper: DMEM, modified Eagle's medium;
DMS, dimethyl suberimidate 2HCl; DMSO, dimethylsulfoxide; DSS,
disuccinimydyl suberate; EGS, ethylene glycol-bis (succinimidyl succi-
nate); FCS, fetal calf serum; FITC, fluorescein isothiocyanate; HPLC,
high performance liquid chromatography; HSA, human serum albumin;
IFN, interferon; IRU, international reference units; Ka, association equi-
librium constant; KIU, kallikrein inhibitory units; KPBS, DMEM with
several laboratories, including our own, have shown that gamma-
interferon (IFNy) can activate mononuclear phagocytes and may
well represent the major type ofMAF produced by physiological
T cell populations (reviewed in references 5 and 6).
These observations have prompted attempts to elucidate the
biochemical basis for IFNy-dependent cellular responses. Re-
cently, we demonstrated the presence of a specific receptor for
IFNy on murine macrophages by its ability to bind ligand in a
saturable, reversible, and specific manner (7). We have also
shown that receptor occupation is a prerequisite for induction
of macrophage tumoricidal activity, Ia antigen expression, or
enhancement of intracellular microbicidal activity (7, 8), bio-
logical activities that are all characteristic of activated macro-
phages.
In the current communication, we wish to extend these ob-
servations to the IFN~y receptor of human mononuclear phago-
cytes. In addition, we report the partial physicochemical char-
acterization of the human monocyte IFN-y receptor and describe
the ultimate fate of the ligand after receptor binding.
Methods
Chemicals, media, and reagents. Media, supplements, and buffers used
in these experiments were purchased or prepared as previously described
(7, 9), and were determined to contain <10 pg/ml of endotoxin using
the Limulus amebocyte lysate assay (Sigma Chemical Co., St. Louis,
MO). Reagents used specifically for this study were purchased from the
following sources: phenylmethylsulfonyl fluoride (PMSF), leupeptin, 43-
phorbol- 1 2( myristate- 1 3a acetate (PMA), dimethylsulfoxide (DMSO),
ATP, and aprotinin were obtained from Sigma Chemical Co.; disuccin-
imydyl suberate (DSS), ethylene glycol-bis (succinimidyl succinate) (EGS)
and dimethyl suberimidate 2 HCO (DMS) were purchased from Pierce
Chemical Co., Rockford, IL.
Interferons. Natural human IFNy was induced from partially purified
human peripheral blood lymphocytes essentially as described by Blalock
et al. (10). Lymphocytes at 6 X 106 cells/ml in RPMI medium containing
1% fetal calf serum (FCS) were stimulated with 1 sg/ml staphylococcal
enterotoxin B (SEB, Sigma Chemical Co.) for 24 h. The resulting culture
supernatants were cleared of cell debris by centrifugation and filtration
and stored at -20'C. This preparation had a specific activity of 1.1
X 104 international reference units (IRU)/mg.
Escherichia coli-derived recombinant human IFN-y was produced
as previously described (I 1) and generously provided by Genentech, Inc.
(San Francisco, CA). Two preparations (lots D0002SF and E9026A)
were used that had been purified to specific antiviral activity of 6.8 and
2 x 107 IRU/mg, respectively. IFNy was stored at 40C in phosphate-
buffered saline (PBS), pH 6.5.
Human alpha and beta interferons were purchased from Lee Biomo-
lecular Laboratories, San Diego, CA. The unpurified preparations had
potassium-PBS; MAF, macrophage activating factor; NP40, Nonidet P-
40; PAGE, polyacrylamide gel electrophoresis; PMA, phorbol myristate
acetate; PMSF, phenylmethylsulfonyl fluoride; SEB, staphylococcal en-
terotoxin B; WGA, wheat germ agglutinin.
2196 A. Celada, R. Allen, I. Esparza, P. W. Gray, and R. D. Schreiber
J. Clin. Invest.
© The American Society for Clinical Investigation, Inc.
0021-9738/85/12/2196/10 $1.00
Volume 76, December 1985, 2196-2205
specific activities of 2.1 X 10 IRU/mg for alpha interferon and I X 10'
IRU/mg for beta interferon.
Preparation of radioiodinated IFN-y. Purified recombinant human
IFN-y (57 Ag) was labeled with 1251I Bolton-Hunter reagent (1 mCi) (ICN
Chemicals, Radioisotope Division, Irvine, CA) for 2 h at 4VC as described
(7). Protein associated and free 1251 were separated by centrifugation
through Biogel P6. Typical preparations displayed specific activities of
8.3 ACi/,ug (13 11Ci/106 IRU). 125I-IFN-y was further purified by gel fil-
tration on a high performance liquid chromatography (HPLC) system
using a 7.5 x 300-mm Biosil TSK 125 column (Bio-Rad Laboratories,
Richmond, CA) (7). Fractions were collected in tubes containing '/I0 vol
of heat-inactivated FCS. IFNy-specific activities were determined either
with a cytopathic effect assay, which used purified vesicular stomatitis
virus, human WISH cells, and the National Institutes of Health human
IFNy standard, or by IFNy-specific radioimmunoassay (Centocor, Inc.,
Malvern, PA). Values obtained with the two assays were in close agree-
ment. Radioiodinated IFN-y was stored at 4VC and retained biological
activity for at least 2 wk.
Monoclonal antibodies. Monoclonal antibodies to recombinant hu-
man IFN-y (HGI/M6 and HGI/M 125) were produced by fusion of im-
mune murine splenocytes with the hypoxanthine, aminoplerin, and thy-
midine (HAT)-sensitive murine myeloma cell line P3 X 63-Ag8.653 at
a splenocyte/myeloma ratio of 10:1 using a previously described fusion
protocol (8). The resulting hybridomas were cloned three times by limiting
dilution. Specificity was confirmed by enzyme-linked immunosorbent
assay and radioimmunoassays that used recombinant human IFNy as
antigen. In functional assays, the antibodies were found to neutralize the
antiviral activity of natural human IFN-y. Purified M6 and M 125 were
prepared by protein-A chromatography of clone culture supernatants.
M6 and M125 are IgG,, K, type antibodies. Monoclonal antibody 543
is specific for the human C3b receptor and was produced as described
elsewhere (12). Monoclonal anti-CR3 a-chain (OKM 10) and ,B-chain
(60.3) were obtained from Ortho Diagnostics, (Raritan, NJ) and from
Dr. Patrick Beatty (Fred Hutchinson Cancer Research Center, Seattle,
WA), respectively. Hamster monoclonal antibodies against murine IFNy
(H22) were prepared as described previously (8).
Monocytes. Human monocytes were purified by Ficoll-Hypaque
centrifugation and centrifugal elutriation. As starting material, mono-
nuclear cell-enriched leukocyte concentrates were used that were obtained
from normal donors undergoing lymphocytapheresis on a continuous
flow centrifugation machine (model 2297; IBM, Princeton, NJ). 80 ml
of concentrate (containing - 108 leukocytes) was diluted 1: 1 with sterile
0.9% sodium chloride and 4 ml layered into tubes containing 10 ml of
Lymphopaque (Nyegaard and Co., Oslo, Norway). After centrifugation
for 20 min at 23°C at 800 g, the mononuclear cells were collected, washed,
and resuspended in 10 ml of elutriation medium (DMEM) with potas-
sium-PBS (KPBS) containing 0.1 M NaCl, 0.002 M KCI, 0.01 M
KH2PO4, 0.008 M Na2HPO4, and 250 mg/ml U. S. Pharmacopeia sterile
human serum albumin (HSA) (Armour Pharmaceutical Co., Kankakel,
IL) (DMEM-KPBS-HSA). The cells were injected into the loading
chamber of an elutriation system (JE-6B Elutriation System, Beckman
Instruments, Inc., Palo Alto, CA) and introduced into the separation
chamber with 125 ml DMEM-KPBS-HSA buffer at a flow rate of 5 ml/
min and a rotor speed of 2,000 rpm. Thereafter, two 100-ml fractions
were collected at flow rates of 13 and 15 ml/min, and 11 50-ml fractions
were collected at flow rates of 16.0, 16.5, 17.0, 17.5, 18.0, 18.5, 19.0,
19.5, 20.0, 21.0, and 22.0 ml/min. Monocyte-containing fractions (6-
13) were combined and collected by centrifugation at 400 g for 10 min.
The resulting cell preparation contained >95% monocytes as assessed
by cytocentrifugation (Cytospin 2, Shandon Instruments, Sewickley, PA)
and Giemsa-peroxidase staining (13) and displayed 99% viability.
Cultured cell lines. The human monocytic cell line U937 (14) and
the promyelocytic cell line HL60 (15) were maintained in RPMI sup-
plemented with 2 mM L-glutamine, 50 U/ml penicillin, 50 ug/ml strep-
tomycin, 1 mM sodium pyruvate, 0.075% (wt/vol) sodium bicarbonate,
and 10% heat-inactivated FCS.
Membrane preparations. U937 cells were lysed by nitrogen cavitation
and the plasma membranes purified in sucrose gradients using a modi-
fication of the method described by Jesaitis et al. (16, 17). Briefly, U937
cells (2 X 109) were washed and then suspended in 20 ml of homoge-
nization buffer (10mM Hepes, 0.34 M sucrose, 0.1 mM MgCl2, 10mM
EDTA, 1 mM dithiothreitol, 250 mM ATP, and 23 kallikrein inhibitory
units (KIU)/ml aprotinin) in a 50-ml polyethylene tube containing a
cylindrical stir bar. The cell mixture was placed in a Parr cell disruption
bomb (Parr Instruments, Moline, IL) that had been precooled to 0C.
The stirred cell mixture was equilibrated for 15 min at 600 psi N2 at
0C. After cavitation, 90% of the starting volume was recovered and the
lysate was immediately centrifuged at 1,000g for 5 min. The foam residue,
which floated on top of the supernatant from this centrifugation, was
collected and homogenized with buffer in a Dounce homogenizer and
combined with the first low-speed supernatant. The mixture was cen-
trifuged again for 5 min at 1,000 g. The supernatant of the second cen-
trifugation was collected and layered into tubes containing sucrose gra-
dients prepared with Hepes buffer. The gradients consisted of a 3-ml
cushion of 60% sucrose and a 22-ml linear gradient ranging from 55 to
20% sucrose. The samples were centrifuged in a Sorval TV 850 vertical
rotor (DuPont Co., Newton, CT) at 45,000 rpm (163,000 g) for 1 h at
40C, and 1.5-ml fractions were collected. Fractions were frozen in liquid
nitrogen and stored at -80'C. In some experiments, U937 were surface
labeled using '25I-wheat germ agglutinin (WGA) according to the pro-
cedure described by Jesaitis et al. (17).
Binding studies with '25I-recombinant IFNy. The method used to
quantitate cellular binding of IFN-y has been described in detail elsewhere
(7). In brief, cells were incubated at 4°C for 2 h with varying amounts
of radiolabeled human IFNy. Free and cell-associated '25I-IFNy were
separated by centrifugation through pthalate oil. Specific binding was
defined as the difference between total binding and the binding that
occurred in the presence of a 100 to 1000-fold excess of unlabeled IFN-y
(nonspecific binding).
To study binding of IFNy to isolated cell membranes, 200 jug of
purified U937 membranes were incubated for 1 h with varying amounts
of 1251-IFNy in a total volume of 100 ,d in RPMI-1640 containing 5%
FCS and 1% Nonidet P40 (NP40) (Sigma Chemical Co.). Free and
membrane-bound IFN-y were separated by ultracentrifugation at 4°C in
a L8-70 ultracentrifuge (Beckman Instruments, Inc.) for 45 min at 40,000
rpm (154,000 g) using a LP42Ti rotor. Specific binding was quantitated
as above.
Binding assays in the presence ofdigitonin or saponin. Five-million
U937 cells were preincubated in I ml ofassay medium (Hanks' balanced
salt solution) containing 10 mM Hepes, 10 mM N-Tris[hydroxy-
methyl]methyl-2-aminoethane sulfonic acid (TES), and 10 mg/ml bovine
serum albumin (BSA) (U. S. Biochemical Corp., Cleveland, OH), 0.1%
glucose, 1 mM PMSF, and 5 ,g/ml of leupeptin, pH 7.4) at 4°C for 15
min in the presence or absence of0.055% digitonin (Matheson, Coleman
and Bell, Norwood, OH) (18) or 0.5% saponin (Sigma Chemical Co.)
(19). Digitonin was added from a stock solution (14 mg/ml) in absolute
ethanol. Control cells for the digitonin experiments received an equal
volume of absolute ethanol. Treated cells were then incubated with ra-
diolabeled IFNy either alone or in the presence of excess unlabeled IFNy
for 2 h at 4°C. Binding was assessed by the centrifugation through oil
method.
Preparation offluorescenated human IgG,. Fluorescein isothiocyanate
(FITC) labeling of a human myeloma IgGl (generously provided by Dr.
H. Spiegelberg, Department ofImmunology, Research Institute ofScripps
Clinic, La Jolla, CA) was accomplished by incubation of 1 mg/ml protein
with 2 mM FITC (Molecular Probes Inc., Plano, TX) in 10 mM borate
buffer, pH 9.7, for 30 min at 37°C. Bound and free FITC were separated
by gel filtration on a 10-ml Biogel P-6 column (Bio-Rad Laboratories).
Protein concentration was determined by the method of Lowry (20).
Quantitation ofIFN-y-dependent induction ofFc receptors. Induction
of Fcy receptors on U937 was measured with a direct immunofluores-
cence assay. Three-million U937 in 10 ml of IFN-y-containing medium
were incubated for 48 h at 370C in T25 tissue culture flasks (3013, Falcon
Labware, Oxnard, CA). Cells were harvested and incubated (1 X 106) at
4°C for 45 min with IO`7 M FITC-labeled human IgGI in a total volume
of 50 ,l. To determine nonspecific binding, cells were preincubated with
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50 zd of 10' IgG1 before addition of fluorescenated ligand. After incu-
bation, cells were washed two times with PBS containing 0.5% HSA and
10 mM sodium azide. Cellular fluorescence was quantitated by flow
cytometry with a FACS IV instrument (Becton-Dickinson & Co., FACS
Systems, Mountain View, CA) using linear amplification. The data are
presented as the difference between the fluorescence intensity (mean flu-
orescence channel number) of cells incubated either with IFNy or me-
dium.
Induction ofcellular differentiation. Purified monocytes from normal
donors were allowed to mature into macrophages by suspension culture
in 50-ml teflon beakers (Nagle Co., Rochester, NY) at 370C in a 5% CO2
atmosphere (21). Each beaker contained 20 X 106 monocytes in 40 ml
of RPMI-1640 supplemented with 5 X 10-2 M 2-mercaptoethanol, 2
mM L-glutamine, 50 U/ml penicillin, 50 ,g/ml streptomycin, and 10%
autologous serum. Cultures were fed every 3 d. Maturation ofU937 cells
was induced by 5 ng/ml PMA and incubation for 5 d (22). HL60 were
differentiated to macrophages by culture with PMA (5 ng/ml) for 5 d
(23) or to granulocytes by culture with DMSO (1.25% vol/vol) for
5 d (24).
Monocyte maturation was assessed morphologically by light mi-
croscopy and cytochemically by loss of peroxidase positivity. Differen-
tiation in U937 or HL60 was confirmed by induction of C3bi (CR3)
and Fc receptors and conversion of the cells to an adherent population.
Uptake and degradation ofIFNy. These studies were performed in
6-well tissue culture plates (Costar, No. 3506, Cambridge, MA) that had
been preincubated overnight with medium containing 20% FCS. The
wells contained 5 X 106 purified human monocytes and 200 ng 1251.
IFNIy in 1 ml of medium. After various lengths of time at 37°C, the
culture supernatants containing unbound or degraded 125IIFNy were
collected. The supernatants were mixed with 500 Ml of FCS and I ml
20% TCA at 4°C and TCA soluble and insoluble material separated by
centrifugation at 4°C for 20 min at 2,000 g. Monocytes were washed at
4°C, solubilized with 1% NP40, and counted for the determination of
total cell-associated radioactivity. As a control, '25IIFNly was incubated
at 37°C in empty wells, then processed as above. The control levels of
TCA soluble counts were subtracted as background from all data points.
An increase in TCA-soluble '25I-IFN-y in the absence of cells was never
observed.
Cross-linking ofmembrane components to '25I-IFNy and SDS-poly-
acrylamide gel electrophoresis (PAGE) analysis. 200 Mg of membrane
protein corresponding to -5 X 107 U937 were incubated with 160 ng
125IIFNJy for 2 h at 4°C. In parallel, a control tube was incubated with
a 100-fold excess of unlabeled IFN-y. Membranes were washed by cen-
trifugation in an airfuge (Beckman Instruments Inc.) for 30 min at 25
psi (120,000 g). Pelleted membranes were resuspended in 45 Ml of PBS,
pH 7.3, and 5 Ml was added ofa 10-mM solution of selected cross-linking
agents (DMS, DSS, or EGS) dissolved in DMSO. After incubation for
20 min at 4°C, 100 Ml of 20 mM Tris HCI, pH 7.3, was added and the
membranes were washed again and resuspended in 50 Ml of 1% NP40.
After 30 min at 4°C, 50 Ml SDS sample buffer was added and membranes
were fractionated by SDS-PAGE using 4-12% polyacrylamide gradient
slab gels as described by Laemmli (25). The SDS sample buffer contained
100 mM dithiothreitol. Gels were dried and autoradiography performed
at -70°C with XAR-5 film (Eastman Kodak Co., Rochester, NY) and
a Cronex Lightning Plus intensifying screen (DuPont Co.). The following
proteins were used as molecular weight markers: myosin (Mr = 20,000),
fl-Galactosidase (Mr = 116,250), phosphorylase B (Mr = 92,500), BSA
(Mr = 66,200), and ovalbumin (M, = 45,000) (Bio-Rad Laboratories,
Chemical Division).
In some cases, whole cells were used as the receptor source. U937 (2
X 108 cells) were incubated in 5 ml of medium (PBS with 0.20 KIU/ml
of aprotonin and 1 mM PMSF, pH 7.3) containing 200 ng '251-IFNy
for 2 h at 4°C. Cells were washed twice with ice-cold medium and cross-
linking was initiated by resuspension of the cells in 5 ml of 1 mM cross-
linking reagent. After incubation for 20 min at 4°C, 10 ml of 20 mM
Tris HCI, pH 7.3, was added and the cells were washed again by cen-
trifugation. Cells were lysed in a Dounce homogenizer and the lysates
were centrifuged at 500 g for 10 min. The supernatants were centrifuged
again at 40,000 g for 30 min at 40C. The high speed pellets were extracted
with 100 Mil of 1% NP40 for 30 min at 4VC, treated with 100 Ml ofSDS
sample buffer, and subjected to SDS-PAGE analysis as above.
Results
Demonstration ofa specific IFN-y receptor on Monocytes, U937,
and HL60. The IFNy receptor of human mononuclear phago-
cytes was defined in ligand binding experiments. These studies
used radioiodinated recombinant human IFNy that had been
subjected to HPLC gel filtration to remove any degraded material
that may have formed during storage. As detected by ultraviolet
absorption at 280 nm and radioactivity, IFNy eluted from the
column at an Mr of 35,000 (data not shown). 62% ofthe recom-
binant IFNy was recovered after iodination and column puri-
fication. The '25I-IFNy displayed antigenic reactivity with
monoclonal anti-IFNy and retained 80% of its starting specific
antiviral activity and 90% of the capacity to induce Fc receptors
on U937.
Fig. 1 shows that '25I-recombinant human IFNy binds to
peripheral blood human monocytes or U937 in a specific and
saturable manner at 4°C. In these experiments, 96-98% of the
total binding was specific, since it was blocked in the presence
of a 100- and 1,000-fold excess of unlabeled IFN'y, respectively.
Binding was homogeneous, noncooperative, and of moderately
high affinity. Binding did not require the presence of calcium
or magnesium ions. Specific binding of 1251-IFNy to HL60, the
human promyelocytic cell line, was also demonstrable. Mean
values for the receptors on the different cell types are listed in
Table I. Whereas the receptors on all three cell types displayed
virtually identical association equilibrium constant (K.) values,
receptor expression on U937 and HL60 was 40-55% lower than
on monocytes. Two different preparations of radiolabeled re-
combinant IFNy produced similar values.
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Figure 1. Quantitation of IFNy binding to monocytes and U937.
5 X 10' cells were incubated at 4VC for 2 h with different amounts of
radiolabeled, HPLC-purified, recombinant IFN'y. Cell associated and
free 25I-IFNy were separated by centrifugation over pthalate oil as
outlined in Methods. Specific binding (solid lines) was defined as the
difference between total binding (dotted lines) and the nonspecific
binding occurring in the presence of a 1,000-fold excess of unlabeled
IFN~y. The inset represents Scatchard analysis of the data. B, bound
IFNy; F, free IFNy.
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Table I. Number ofIFNy Receptors and Ka
on Human Monocytes U937 and HL60
IFNy Number of K. X 10-8
Cell type preparation experiments Receptors/cell (M-')
Monocytes D 0002 SF 5 6,900±1,000* 4.0±2.3
U937 D 0002 SF 20 4,200±1,000 5.0±3.4
HL60 D 0002 SF 3 3,200±700 4.1±1.8
U937 E 9026 A 15 5,500±1,600 12.1±4.7
* Mean±SD. Monocytes were obtained from five different normal in-
dividuals. The quantitation of IFN'y binding was determined as de-
scribed in Fig. 1.
The specificity of the binding reaction is demonstrated in
Fig. 2. Crude preparations of natural human IFNy (SEB-stim-
ulated lymphocyte culture supernatants) efficiently competed
with '25I-recombinant IFNy for binding to U937 (67% inhibition
was achieved at inputs of 6,800 IRU natural and 2,040 IRU
'25I-rIFNy). Crude preparations of natural human IFNf3 dis-
played only a weak ability to inhibit binding of recombinant
IFN-y when added in large excess (100,000 IRU), while natural
human IFNa displayed no inhibitory activity. Lower doses of
IFNa or IFNI3 were not inhibitory at all. Monoclonal antibodies
(M6 and M125) specific for human IFN-y, which neutralized
IFNy biological activity, abrogated specific IFNy binding to
U937. Other monoclonal antibodies that did not react with hu-
man IFNy (H22, 543, OKM 10) were without effect on the bind-
ing reaction.
Fig. 3 demonstrates that the binding of IFNy to U937 was
reversible, since bound ligand dissociated from the cells in a
homogeneous manner. The t112 for the dissociation was 68 min
at 4°C and the reaction could be described by a single dissociation
rate constant (koff) of 9 X 10-5 S-1.
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Figure 2. Specificity experiments for recombinant l2I-IFN4y binding
to macrophages. U937 cells were preincubated for 30 min at 4°C with
designated amounts of competitor in a total reaction volume of 100
Ml. 20 Al of '25I-IFNy (30 ng) was then added to each tube and incuba-
tion continued for 2 h at 4°C. Specific binding and separation of
bound and free 1251I-IFN-y as in Fig. 1. For these studies, the natural
IFN-y was concentrated 10-fold before use by ultrafiltration. A sham
supernatant concentrated 10-fold did not have any inhibitory effect on
the '25[1IFNy binding to the cells.
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Figure 3. Dissociation of bound IFNy from U937. Sixty-million U937
were incubated in I ml of medium containing 800 ng of 125I.IFN-y for
2 h at 4°C. Cells were washed and resuspended to the original volume
in the presence of a 100-fold excess of unlabeled IFNy. At designated
times, aliquots of 5 X 106 cells were centrifuged through phthalate oil
and the radioactivity in the cell pellet measured. The data are pre-
sented as the log of the percentage of IFNy remaining bound to the
cells. Zero time is taken as 100%. The specific IFNy binding at zero
time was 0.90 ng/5 X 101 cells.
Demonstration that occupation ofthe IFNy receptor induces
a cellular response. The biological relevance of the receptor was
validated by assessing the relationship between receptor occu-
pancy and stimulation ofa functional response in mononuclear
phagocytes. For this purpose we measured the IFNy-dependent
induction of Fc receptors on U937 (26, 27). Fig. 4 depicts the
dose-response profile for Fc receptor induction by purified hu-
man recombinant IFNy. 50% maximal induction was produced
by 3 ng of IFN'y (60 IRU) and maximal stimulation occurred
at 50 ng input (1,000 IRU). When the data from the above
experiment and the receptor binding experiments were nor-
malized to similar cell densities (Fig. 4, inset), the concentration
of IFN-y required for cell binding was found to correlate with
that needed to induce the cellular response.
Ontogeny ofthe IFN'y receptor on mononuclear phagocytes.
The ability to differentiate U937, HL60, and peripheral blood
monocytes in vitro provided a mechanism to study the ontogeny
of the IFNy receptor. Table II demonstrates that receptor
expression and affinity was not altered when normal peripheral
blood monocytes matured to macrophages by 6-8 d culture in
teflon beakers or when U937 and HL60 were differentiated into
monocytes/macrophages by 5 d culture with PMA. No changes
in the receptor were noted even when HL60 was induced to
become granulocytes by treatment with DMSO.
In all experiments, differentiation was confirmed by mor-
phological, cytochemical, and immunochemical analysis (see
Methods). After 5 d induction with PMA, >90% of the U937
and 86% ofHL60 expressed monocyte/macrophage markers and
morphology. After 5 d incubation with DMSO, the HL60 culture
consisted of 6.1% promyelocytes, 65.3% myelocytes, 24.6%
metamyelocytes, 1.6% band cells, and 2.4% mature polymor-
phonuclear leukocytes.
Protease sensitivity of the IFN-y receptor. Pretreatment of
U937 with 1 mg/ml trypsin or pronase for 5 min at 37°C ab-
rogated subsequent binding of '25I-IFNy at 4°C (Fig. 5). Whereas
5 X 106 untreated cells bound 1.4 ng of IFN'y at saturation, the
same number of trypsin-treated cells bound only 0.18 ng and
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Figure 4. Correlation between IFNy receptor occupancy and induc-
tion of Fc receptor expression on U937. Three-million cells were incu-
bated in 10 ml with various amounts of IFNy for 48 h at 370C. Fc
receptors were quantitated by direct immunofluorescence on a flow
pronase-treated cells only 0.07 ng of ligand. These values rep-
resent an 87-95% reduction of IFNy binding and suggest that
the receptor is a protein.
cytometer as described in Methods. Inset: Comparison of IFNy recep-
tor occupancy and induction of Fc receptors. The IFNy input has
been expressed in molarity and adjusted to 106 cell/ml.
Intracellular and extracellular distribution ofIFN-y receptors.
Saponin and digitonin have been used by others to permeabilize
cells, and allow quantitation of intracellular (or cryptic) and
extracellular receptors ( 18, 19). In order to obtain these values
Table II. Cellular DifJerentiation Does Not
Alter IFN'y Receptor Expression
Number of K. X 10-8
Cell type experiments Receptors/cell (M-')
Monocytes:
Control 2 7,900±400 4.9±1.2
After maturation 7,800±400 5.0±0.8
U937:
Control 3 4,000±1,200 4.6±2.07
After induction 4,400±1,200 3.9±0.96
HL60:
Control 2 3,600±800 4.4±0.7
After induction (PMA) 3,400±1,000 4.3±1.6
After induction (DMSO) 4,000±400 4.5±1.1
Maturation was induced in monocytes by culture in teflon beakers for
6 or 8 d. Maturation in U937 was induced by culture with PMA for 5
d. The promyelocytic cell line HL60 was differentiated into monocytic
cells by incubation with PMA or into granulocytic cells by incubation
with DMSO.
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Figure 5. Effect of protease treatment on IFNy binding by U937 cells.
Three sets of 50 x 106 cells were washed with EDTA and then incu-
bated for 5 min with medium or 1 mg/ml of pronase or trypsin in a
total volume of 50 ml. Cells were washed and IFNy binding studies
were carried out as outlined in Fig. 1.
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for the IFNy receptor, the binding studies were repeated on
U937 with these agents. In the presence of 0.055% digitonin,
U937 specifically bound 10,200 IFNy molecules per cell, while
untreated U937 bound only 4,700 IFNy/cell (Fig. 6). Digitonin
did not release prebound 125I-IFNy, indicating that the perme-
abilization procedure did not cause extraction of receptors. The
binding affinity of the total receptor pool was comparable to the
Ka values of only the external receptors. By calculation, the in-
tracellular receptors were estimated to comprise 54% ofthe total
cellular receptor pool. Similar values for the intracellular levels
ofreceptor were obtained in two other experiments with digitonin
(48 and 52%) or when 0.5% saponin was used as the permeabil-
ization agent.
Receptor-mediated internalization of IFN-y. Whereas the
binding of IFNy to U937 was homogeneous at 4°C, it was bi-
modal at 37°C (Fig. 7, left). The lower affinity binding at 37°C
(1.7 X l09 M-') was of similar magnitude to that observed at
40C (3.0 X 109 M-1). In addition, a high affinity binding of
IFNy to the cells was observed at the elevated temperature
(2.3 X 1010 M-').
The high affinity binding observed at 37°C appeared to be
a result of ligand internalization and not expression of different
classes of receptors. This conclusion was reached because (a)
purified U937 membranes bound IFNy with a single affinity at
either 4°C (1.2 X l09 M-') or 370C (i.5 X l09 M-') (Fig. 7,
right); (b) at either temperature, whole paraformaldehyde-fixed
U937 displayed only a single binding affinity for ligand (0.9
X 109 M- at 40C, 0.8 X 109 M` at 37°C); and (c) IFN-y inter-
nalization could be directly demonstrated at 370C (Table III).
In this last study, monocytes bound 33% more ligand at 370C
than at 4°C. When monocytes that had bound IFN-y at 40C
were stripped of surface receptors by trypsin treatment, the
number of cell-associated IFN-y molecules decreased from 5,300
to 700/cell. In contrast to this result, cells that had been exposed
to ligand at 370C maintained 2,300 molecules of '25I-IFNy/cell
Figure 6. Binding of IFNy to U937
cells in the presence and absence of
0.055% digitonin. Cells (5 x 106) were
incubated with ligand at 4VC for 2 h
in a total volume of 1 ml. To one set
of tubes, digitonin (14 mg/ml in
ethanol) was added to a final concen-
tration of 0.055%. Control tubes re-
__j ceived an equivalent concentration of
240 ethanol. The reaction was terminated
by spinning the cells and counting the
pellets and the supernatants.
after enzyme treatment. When Scatchard analysis was performed
on the reaction mixtures before and after trypsin stripping, an
apparent 12.5-fold increase in the Ka was observed.
Degradation ofinternalized '25I-IFNy. The temperature de-
pendent conversion of 1251I-IFNy to TCA soluble degradation
products is shown in Fig. 8. At either 40 or 370C, cellular
uptake of radiolabeled ligand reached a maximum after 10 min
and remained essentially unchanged for the next 3.5 h. Maxi-
mum binding at 370C (1.7 ng) was 30% greater than at 4 C (1.3
ng) (data not shown). At 40C, no IFN'y degradation was observed
20 0
Bound (fmol)
Figure 7. Effect of temperature on IFN-y interaction with whole U937
cells and membranes. (Left) U937 cells (5 X 106) were incubated with
125I-IFN-y at 40 or 37°C for I h in a total volume of 100 Al. Cell
associated and free ligand were separated by centrifugation through
pthalate oil. (Right) 200 ,ug of purified U937 membranes were incu-
bated at 4°C or 37°C for 1 h in a total volume of 100 p1. Free and
membrane-bound radiolabeled IFNy were separated by ultracentrifu-
gation. Nonspecific binding in both cases was determined by addition
of 100-fold excess of unlabeled IFNy.
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Table III. Internalization ofIFN-y by Monocytes
Incubation Trypsin K, X 1O-8
temperature stripping IFNy molecules/cell (M-')
°C
4 - 5,300 4.7
4 + 700 4.9
37 - 7,000 4.1
37 + 2,300 52.0
5 X 106 purified monocytes were adhered per well in six well tissue
culture plates. Different amounts of IFNy were added to the plated
monocytes in a total volume of 1 ml. Two sets of monocytes were in-
cubated for 2 h at 4VC and another two at 370C. Then, one set of pre-
viously incubated monocytes at 4VC and another at 370C were
washed and treated with trypsin. The two other sets were only washed.
Finally, 1% NP40 was added, cells were lysed, and the radioactivity as-
sociated with the cells counted.
over the 4-h period (Fig. 8). However, TCA soluble radioactivity
became detectable in culture supernatants of monocytes held at
370C for 2 h and increased linearly for the next 2 h. Based on
the specific activity ofthe radioiodinated IFNy, degradation was
estimated to occur at a rate of 5,000 molecules/cell per h.
Characterization ofthe human monocyte IFNy receptor by
SDS-PAGE. The data presented thus far defined the IFN'y re-
ceptor ofhuman mononuclear phagocytes by classical biochem-
ical and functional criteria. We also wished to chemically define
the receptor molecule. Initial attempts to directly radioiodinate
the receptor on whole U937 cells and affinity purify it on IFNy-
coated beads were unsuccessful probably due to the limited
number of receptor molecules expressed at. the plasma mem-
brane. However, since highly purified, radiolabeled ligand was
available, we directed our efforts at affinity labeling the receptor
by chemically cross-linking it to specifically bound '25I-IFN.
In preliminary experiments, cross-linking was confirmed by
10 -
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were prelabeled with 1251WGA subjected to N2 cavitation, and puri-
fied by sucrose density gradient cen~trifugation for 1 h at 163,000 g.
The distribution of 1251 WGA, protein, and sucrose is shown as a func-
tion of the relative volume collected from the sucrose density gradient.
demonstrating a reduction in the dissociation rate of ligand from
the cell surface (data not shown).
In order to minimize the possibility of proteolysis of the
ligand-receptor complex (and reduce nonspecific labeling),
plasma membrane-enriched fractions were prepared from U937
cells by N2 cavitation and subsequent isopyknic sucrose density
gradient sedimentation of the homogenate as outlined in the
methods section. Plasma membrane recovery was determined
by the presence of'252-WGA, which had been used in trace
amounts to surface label the cells. 94% ofthe radioactivity applied
to the gradients was sedimentable (total recovery was 95%) and
recovered as a single band with a peak at a density of 1.286 g/
c-m (30% wt/vol sucrose) (Fig. 9). This fraction carried 23% of
the total 1251-WGA and only 5.6% ofthe total protein. Thereafter,
the same fraction from gradients of unlabeled membranes was
used as the membrane source.
Membrane preparations were incubated with '25fIrFomU
cross-linked, solubilized, and then analyzed by SDS-PAGE under
reducing conditions. Fig. 10 depicts an autoradiograph of a
Mr
200 K-
116 K-
92 K-
66 K-
45 K-
2 3
Time of Incubation (hours)
4
Figure 8. Degradation of IFNy by monocytes. 5 X 10' of elutriation-
purified cells were adhered per well in six well tissue culture plates.
200 ng of '25I-IFNy was added to each well and cultured at 4°C or
37°C for different periods of time. Then supernatants were harvested,
mixed with FCS, and precipitated with TCA. TCA soluble and insolu-
ble radioactivity was quantitated. Cells were washed, solubilized with
1% NP40, and radioactivity counted.
Figure 10. Cross-linking of '25I-
IFNy bound to membranes of
U937 cells and analysis by Na-
DodSO4/PAGE. 200 ,g of purified
membranes were incubated with
160 ng of 25I..lNy for 2 h at 4°C,
washed, and treated with I mM
DSS. After washing, membranes
were extracted and analyzed by
NaDodSO4/PAGE followed by au-
toradiography (lane 1). In parallel,
membranes were preincubated
with a 100 excess cold IFN-y (lane
2 2). K, hundred-thousand.
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preparation cross-linked with 1 mM disuccinimidyl suberate
(DSS). The sample in lane I represents membranes that were
reacted with labeled IFN'y. A wide radioactive band is visible
with an M, of 94,000. This band has been observed in nine
different experiments that used three different membrane prep-
arations. The average M, for the top and bottom portions ofthe
band were 104,000+18,000 and 84,000±6,000, respectively. The
band was not observed when the U937 membranes were pre-
treated with a 100-fold excess of unlabeld IFNy (Fig. 10, lane
2), when the radioiodinated ligand was preincubated with a
monoclonal anti-IFNy (M125) that inhibited binding of IFNy
to cell surfaces (data not shown) or when the cross-linking agent
was omitted (data not shown).
The two bands at the bottom of both tracks display Mr of
17,000 and 34,000, and are consistent with the presence ofpoly-
peptides, having molecular weights corresponding to a single
IFNy polypeptide chain and an internally cross-linked polypep-
tide chain dimer. These bands appear in the presence or absence
ofunlabeled IFN-y and are therefore presumed to be nonspecific
and possibly represent free ligand carried through the washing
procedure.
The high molecular weight band shows cross-linker selectiv-
ity. The band was observed only when DSS or EGS were used
as linking agents but not when DMS was employed. DSS cross-
linked preparations produced clearer autoradiographs than EGS
samples. DSS cross-linking was dose dependent. At concentra-
tions of 0.2 mM, no cross-linking occurred, while at high con-
centrations (30 mM), the samples were so heavily cross-linked
that they did not enter the SDS gel. Optimal results were obtained
at 1 mM linking agent.
In two experiments, whole U937 cells were used as the re-
ceptor source. The autoradiographs showed a complex band in
which the Mr of the top was 107,000± 10,000 and was
87,000±700 at the bottom. These results thus agree with those
of the purified membrane preparations.
Discussion
The data presented in this report serve to define and partially
characterize the IFNy receptor on human mononuclear phago-
cytes. These studies represent a detailed analysis of the receptor
on this cell type and are particularly warranted because mono-
cytes and macrophages represent a major target of the immu-
nomodulatory actions of IFNy. Binding of radioiodinated, pu-
rified recombinant human IFN'y to human peripheral blood
monocytes U937 and HL60 at 4°C was noncooperative, satu-
rable, reversible, and of moderately high affinity (Ka = 0.5-1.0
X 109 M-'). The interaction was specific because uptake of ra-
diolabeled ligand was inhibited only by unlabeled natural or
recombinant IFNy (and not IFNa or IFNf#) or by monoclonal
antihuman IFN-y, which blocked IFNy-dependent antiviral ac-
tivity. The mononuclear phagocyte receptor appeared to be a
protein because IFN-y did not bind to cells treated with trypsin
or pronase. At 37°C, surface-bound ligand was internalized and
could not be eluted from the cells with trypsin. Intracellular
IFNy was degraded into TCA-soluble material at a constant rate
of -5,000 molecules/cell per h.
When binding was performed at 37°C, the Scatchard plot
of the binding data was biphasic. This result could either indicate
the presence of a second high affinity class of IFNy receptors as
suggested by Aiyer et al. (28), or that ligand internalization had
occurred. The first possibility was excluded by the demonstration
that purified membranes and paraformaldehyde fixed U937
bound ligand in a unimodal manner at either 40 or 370C.
Receptor expression and avidity were not influenced by cel-
lular differentiation or activation, and even uncommitted pre-
cursor cells (such as HL60) carried IFN'y receptors on their sur-
face. This observation is compatible with the previously reported
ability of IFNy to induce differentiation of precursor cells such
as HL60 and U937 (29, 30), activate a variety of functions in
mature human monocytes and macrophages (6), and cause ter-
minal differentiation of monocytes to polykarions (31). Thus,
the IFNy receptor appears to be a ubiquitous component of the
mononuclear phagocyte plasma membrane. This conclusion
distinguishes the IFNy receptor from Fc and C3 receptors, since
the latter are expressed only on more differentiated forms of
mononuclear phagocytes (21, 32).
The low magnitude of receptor expression on monocytes
necessitated an indirect analysis approach to study the molecular
weight ofthe receptor. Cross-linked preparations ofradiolabeled
ligand and purified plasma membranes migrated on SDS-PAGE
as a wide band that spanned a molecular weight range of 87,000-
104,000. While this apparent heterogeneity may reflect a high
level of receptor glycosylation, it is more likely that it results
from the formation of a cross-linked complex between the
membrane component and either the internally cross-linked
whole IFNy molecule (consisting of two identical 17,000-mol
wt polypeptide chains) or a single polypeptide chain subunit.
Under the dissociating conditions used in the SDS-PAGE anal-
ysis, the complexes would therefore contain either a 34,000- or
1 7,000-Mr ligand component. By subtracting these values from
the apparent molecular weights at the top and bottom of the
band, the molecular weight of the receptor is estimated to be
70,000. The similarity of the molecular weight estimates made
on different purified membrane preparations and whole cells
suggests that receptor degradation did not occur during pro-
cessing. However, the final assignment of a molecular weight
for the IFNy receptor on mononuclear phagocytes must await
an analysis of the free molecule after documentation of its ligand
binding capability. Attempts are currently being made in our
laboratory to achieve these goals.
Interferon-y induces a wide spectrum of biological activities
in macrophages, including the induction of major histocom-
patibility complex class II antigens, Fc and C3bi receptors, cy-
tocidal activity, and stimulation of ILI production (6). Binding
of IFNy to. its cell surface receptor represents the first step in
the induction of the various macrophage cellular responses. In
our experiments, the concentration of IFNy needed to effect
receptor occupancy closely correlated with that which induced
Fc receptors on U937. Similar concentrations of IFNy have
been reported by others to induce responses in U937 or mono-
cytes. Perusia et al. (26) and Guyre et al. (27) needed between
I and 50 ng IFNy/ml to induce 100% Fc receptor expression
on U937 cells. Nathan et al. (33) reported that 1.2-nM concen-
trations of IFNy (40.8 ng/ml) induced 50% of maximal toxo-
plasmacidal activity in monocytes. The latter experiments used
human IFNy that displayed a specific activity of 6 X 105 U/mg.
Taken together, these results validate the biological relevance of
the IFN'y receptor.
Over a period of 4 h, IFNy was degraded at a linear rate of
'-5,000 molecules/cell per h. This means that the receptors on
the cell surface need to be replaced three times during this time
period. This data is consistent with our previous report (7), which
showed a similar pattern of IFNy absorption by murine mac-
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rophages. It is clear from these calculations that additional re-
ceptors must be recruited to the cell surface during the course
of incubation. These may be derived from (a) a preexisting in-
tracellular pool ofreceptors, (b) recycling ofinternalized receptors
after the dissociation of bound ligand, or (c) de novo synthesis
of additional IFN'y receptors. Increased receptor synthesis does
not appear to be required, since cells treated with cycloheximide
(a protein synthesis inhibitor) bound and degraded IFNy in a
normal fashion (data not shown). Experiments using permeabil-
ized cells demonstrated the presence of cryptic receptors equal
in the number to the receptors at the cell surface. In studies to
be presented elsewhere, receptor recycling was evidenced by the
ability of lysosomotropic agents to inhibit degradation (Celada,
A., and R. D. Schreiber, manuscript in preparation). It is of
interest to note that murine macrophages must be kept in contact
with IFN'y for at least 4 h before tumoricidal activity can be
initiated (7, 34-36). Similar observations have been reported for
IFNy-dependent induction ofantiviral activity in fibroblasts (37).
The possibility thus exists that ligand internalization may play
a role in inducing certain cellular responses. However, other less
complex functions, such as increased hydrogen peroxide pro-
duction, appear to occur as a direct consequence of ligand-re-
ceptor interaction (33). Together, these results indicate that in-
duction of complex biological functions in macrophages may
require more than receptor-mediated signal transduction.
To date, an IFNy receptor has been detected on several dif-
ferent human cell types, including fibroblasts (38-41), lympho-
blastoid cells (42), epitheloid cells (43), and, in preliminary re-
ports, U937 (44) and monocytes (45). At the present time, the
relationship between the IFNy receptors on these cells remains
undefined. On the basis ofthe above studies, all cell types appear
to carry comparable numbers of receptors (103- 104/cell) that
display similar binding affinities at 4VC (K, = 108-109 M-'). The
cross-linked IFNIy-IFNy receptor complex from WISH fibro-
blasts displayed an apparent molecular weight of 105,000 (40),
and from lymphoblastoic cells, 125,000 (42). These values are
comparable to the mean molecular weight of the U937-derived
complex reported herein. Recent experiments, performed in our
laboratory, which directly compared ligand binding to monocytes
and fibroblasts, showed that IFNy bound to the two cell types
with identical affinities (K. = 1.5 and 1.8 X 109 M-1, respectively
(Celada, A., and R. D. Schreiber, unpublished observation). Al-
though this data suggests the presence of a single type of IFNy
receptor on different cells, definitive conclusions must await a
full biochemical and genetic analysis of the receptor.
The identification of an IFNy receptor on macrophages is
the first step toward understanding macrophage activation at
the molecular level. Work is currently in progress to fully char-
acterize the receptor, determine its fate after receptor-ligand
contact, and to assess whether receptor engagement is sufficient
to initiate macrophage activation. These investigations should
provide new insights into the role of IFNy and activated mac-
rophages in host defense.
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